2021年会员

2022年提出的指控

监管框架(b)专责小组

The mission of the 规管架构(B)专责小组 is to: 1) develop NAIC model acts and regulations for state health care initiatives; and 2) consider policy issues affecting state health insurance regulation.

Ongoing Support of NAIC Programs, Products and Services

1. The 规管架构(B)专责小组 will:
   
   1. 就联邦卫生立法和条例提出的州一级实施问题，协调和发展向各州提供的技术援助.
   2. 审查管理下的医疗改革, 他们的服务系统出现在市场和其他形式的医疗服务中. 建议对监管权限、权力和结构进行适当的修订.
   3. 考虑新NAIC示范法律法规的发展和现有NAIC示范法律法规的修订, 包括受联邦立法和根据该立法颁布的最终联邦条例影响的法律.
   4. 继续审查原平价医疗法案(ACA)模型审查(B)工作组建议修订的NAIC模型, 适当的, 任命一个工作组或子小组对2022年优先修订的NAIC模型进行修订.
   5. At the direction of the 健康保险 and Managed Care (B) Committee, 通过雇员退休收入保障法(ERISA) (B)工作组的工作, monitor, 分析和报告 developments related to association health plans (AHPs).
   6. Monitor, 分析和报告, 必要时, 与短期有关的发展, 时间有限(STLD)报道.
2. The Accident and Sickness Insurance Minimum Standards (B) Subgroup will:
   
   1. Review and consider revisions to the 实施事故和疾病保险最低标准示范法示范规则 (#171).
3. The ERISA (B)工作组 will:
   
   1. Monitor, report and analyze developments related to the federal ERISA, 并就NAIC的战略和政策就这些发展提出建议.
   2. Monitor, facilitate and coordinate with the states and the U.S. Department of Labor (DOL) related to sham health plans.
   3. Monitor, 就与ERISA相关的ACA的合规和执行努力，促进和协调各州和DOL.
   4. Review the 雇员退休收入保障法下的健康和福利计划:州和联邦监管指南 (ERISA手册)，并在必要时加以修改，以反映与ERISA有关的发展. 每年的报告.
4. The Mental Health Parity and Addiction Equity Act (MHPAEA) (B) Working Group will:
   
   1. Monitor, 报告和分析2008年联邦Paul Wellstone和Pete Domenici MHPAEA的相关发展, 并就NAIC的战略和政策就这些发展提出建议.
   2. 与各州、美国劳工部和美国政府监督、促进和协调最佳实践.S. Department of Health and Human Services (HHS) related to the MHPAEA.
   3. Monitor, 就与MHPAEA相关的ACA的合规和执行努力，促进和协调各州和DOL.
   4. 提供补充资源以支持NAIC市场法规手册中MHPAEA章节的文件和报告.
   5. 与市场监管和消费者事务(D)委员会各小组协调并提供意见, 必要时, regarding mental health parity market conduct examinations.
5. The Pharmacy Benefit Manager Regulatory Issues (B) Subgroup will:
   
   1. Develop a white paper to: 1) analyze and assess the role PBMs, Pharmacy Services Administrative Organizations (PSAOs), 以及其他供应链实体, play in the provision of prescription drug benefits; 2) identify, 检查和描述当前和新兴国家对PBM商业实践的监管方法, such as price transparency and reporting requirements, 折扣价和差价定价, 包括的影响 拉特里奇和. Pharmaceutical Care Management Association (PCMA) decision on such business practices; and 3) discuss any challenges, if any, the states have encountered in implementing such laws and/or regulations.
   2. 考虑开发一个新的NAIC模型，为药房利益管理人员(PBMs)建立许可证或注册流程. Based on issues identified in the white paper, 该小组可考虑在新的NAIC模式中纳入关于PBM处方药品定价和成本透明度的规定.

2021年修订采用收费

监管框架(b)专责小组

The mission of the 规管架构(B)专责小组 is to: 1) develop NAIC model acts and regulations for state health care initiatives; and 2) consider policy issues affecting state health insurance regulation.

Ongoing Support of NAIC Programs, Products and Services

1. The 规管架构(B)专责小组 will:
   
   1. 就联邦卫生立法和条例提出的州一级实施问题，协调和发展向各州提供的技术援助.
   2. 审查管理下的医疗改革, 他们的服务系统出现在市场和其他形式的医疗服务中. 建议对监管权限、权力和结构进行适当的修订.
   3. 考虑新NAIC示范法律法规的发展和现有NAIC示范法律法规的修订, 包括受联邦立法和根据该立法颁布的最终联邦条例影响的法律.
   4. 继续审查原平价医疗法案(ACA)模型审查(B)工作组建议修订的NAIC模型, 适当的, 任命一个工作组或子小组对2021年优先修订的NAIC模型进行修订.
   5. At the direction of the 健康保险 and Managed Care (B) Committee, 通过雇员退休收入保障法(ERISA) (B)工作组的工作, monitor, 分析和报告 developments related to association health plans (AHPs).
   6. Monitor, 分析和报告, 必要时, 与短期有关的发展, 时间有限(STLD)报道.
2. The Accident and Sickness Insurance Minimum Standards (B) Subgroup will:
   
   1. Review and consider revisions to the 实施事故和疾病保险最低标准示范法示范规则 (#171).
3. The ERISA (B)工作组 will:
   
   1. Monitor, report and analyze developments related to the federal ERISA, 并就NAIC的战略和政策就这些发展提出建议.
   2. Monitor, facilitate and coordinate with the states and the U.S. Department of Labor (DOL) related to sham health plans.
   3. Monitor, 就与ERISA相关的ACA的合规和执行努力，促进和协调各州和DOL.
   4. Review the 雇员退休收入保障法下的健康和福利计划:州和联邦监管指南 (ERISA手册)，并在必要时加以修改，以反映与ERISA有关的发展. 每年的报告.
4. The Mental Health Parity and Addiction Equity Act (MHPAEA) (B) Working Group will:
   
   1. Monitor, 报告和分析2008年联邦Paul Wellstone和Pete Domenici MHPAEA的相关发展, 并就NAIC的战略和政策就这些发展提出建议.
   2. 与各州、美国劳工部和美国政府监督、促进和协调最佳实践.S. Department of Health and Human Services (HHS) related to the MHPAEA.
   3. Monitor, 就与MHPAEA相关的ACA的合规和执行努力，促进和协调各州和DOL.
   4. 提供补充资源以支持NAIC市场法规手册中MHPAEA章节的文件和报告.
   5. 与市场监管和消费者事务(D)委员会各小组协调并提供意见, 必要时, regarding mental health parity market conduct examinations.
5. The Pharmacy Benefit Manager Regulatory Issues (B) Subgroup will:
   
   1. 考虑开发一个新的NAIC模型，为药房利益管理人员(PBMs)建立许可证或注册流程. 该小组可考虑在新的NAIC模式中纳入关于PBM处方药品定价和成本透明度的规定.
   2. Develop a white paper to: 1) analyze and assess the role PBMs, Pharmacy Services Administrative Organizations (PSAOs), 以及其他供应链实体, play in the provision of prescription drug benefits; 2) identify, 检查和描述当前和新兴国家对PBM商业实践的监管方法, such as price transparency and reporting requirements, 折扣价和差价定价, 包括的影响 拉特里奇和. Pharmaceutical Care Management Association (PCMA) decision on such business practices; and 3) discuss any challenges, if any, the states have encountered in implementing such laws and/or regulations.  

NAIC支持人员:Jolie H. 马修斯/詹妮弗·R. Cook